기본 정보
- 표준 SMILES
Cc1cnc(C(=O)O)c[n+]1[O-]- InChIKey
DJQOOSBJCLSSEY-UHFFFAOYSA-N- 분자식
- C6H6N2O3
- 평균 분자량
- 154.12 g/mol
- 단동위원소 질량
- 154.03784205
개요
5-methyl-4-oxido-2-pyrazin-4-iumcarboxylic acid is a pyrazinecarboxylic acid.
이름 및 식별자
- 우선 이름
- Acipimox
- IUPAC
- 5-methyl-4-oxidopyrazin-4-ium-2-carboxylic acid
- 영어명
- Acipimox
- 분자식
- C6H6N2O3
- 분자량
- 154.12
이름 및 동의어
이름 더 보기
데이터베이스 식별자
- CAS
51037-30-0- PubChem CID
- 5310993
- DTXSID
DTXSID2046202- ChEMBL
CHEMBL345714- ChEBI
CHEBI:94688- UNII
- K9AY9IR2SD
- EC Number
- 256-928-3
- Nikkaji
- J10.290C
물성
구조 계산 물성
- XLogP
- -1
- 극성 표면적
- 75.7 Ų
- 수소 결합 공여자 수
- 1
- 수소 결합 수용자 수
- 4
- 회전 가능 결합 수
- 1
- 무거운 원자 수
- 11
- 형식 전하
- 0
- 복잡도
- 162
실험 및 물리화학적 성질
Drugs
Pharmaceuticals -> Antilipidemics
Pharmaceuticals -> Listed in ZINC15
물리화학적 성질
- 녹는점
- 177 · 177-180 °C
- 끓는 점
- 539 · 539.0±45.0 °C(Predicted)
- 밀도
- 1.44 · 1.44±0.1 g/cm3(Predicted)
- 저장 조건
- 2 · Inert atmosphere,2-8°C
- 용해도
- 메탄올, 물(100mM), DMSO(100mM), 에탄올(25°C에서 <1mg/ml) 및 1M NH4OH(1mg/ml)에 용해됩니다.
- 물리적 상태
- 고체
- 산도 계수 (pKa)
- 2.8 · 2.80±0.10(Predicted)
- 색상
- 노란색
- Merck
- 14 · 14,111
- InChI
- InChI=1S/C6H6N2O3/c1-4-2-7-5(6(9)10)3-8(4)11/h2-3H,1H3,(H,9,10)
- InChIKey
- DJQOOSBJCLSSEY-UHFFFAOYSA-N
- SMILES
- C1(C(O)=O)N=CC(C)=[N+]([O-])C=1
- EPA
- 5 · Pyrazinecarboxylic acid, 5-methyl-, 4-oxide (51037-30-0)
화학적 성질
Yellow Solid
안전 및 규제
GHS 분류
GHS Classification
This chemical does not meet GHS hazard criteria for 41.7% (30 of 72) of reports.
Warning
H319 (58.3%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]
P264+P265, P280, P305+P351+P338, and P337+P317 (click each P-code to see the statement)
Aggregated GHS information provided per 72 reports by companies from 3 notifications to the ECHA C&L Inventory.
유해성 정보
안전 데이터
- wgk
- 3
- rtecs
- UQ2453000
- 독성
- LD50 orally in mice: 3500 mg/kg (Ambrogi)
- HS 번호
- 2933.99.8290
- risk_code
- 36
- hazard_code
- Xi
- safety_code
- 26
- 스토리지 클래스
- 11 - Combustible Solids
화학 및 산업
약리 정보
ATC Code
C10AD06
C - Cardiovascular system
QC - Cardiovascular system
응용 분야
개요Acipimox is a nicotinic acid derivate that structurally related to nicotinic acid. Like nicotinic acid, lowers lipids effectively, but unlike nicotinic acid, acipimox is longer acting and therefore much less prone to produce free fatty acid rebounding. It is usually employed in man in the therapy of hypertriglyceridemia. In addition to its lipid lowering activity, it produces a beneficial elevation of the anti-atherogenic high density lipoprotein subfraction, HDL2. Acipimox is recommended as a lipid-lowering agent to treat hyperlipidemia in patients with noninsulin dependent diabetes mellitus.
용도Acipimox is a long-acting antilipemic agent and used for the treatment of hyperlipoproteinemias, in particular hypertriglyceridemias, and as adjunctive therapy for affecting cholesterol metabolism.
제조 방법
Synthesis of acipimox: Under cooling and stirring, 78 g of maleic anhydride was dissolved in a solution of 60 ml of chloroform, and 40 ml of 30% hydrogen peroxide was added. After 2 h, 4.8 g of 5-Methyl-2-pyrazinecarboxylic acid was added, and the temperature was kept at 0-5 °C for 2 d. The maleic acid was filtered off. Concentrate to a small volume, add ethyl acetate, and filter to obtain 1.1 g of acipimox, the melting point of which is 178-180 °C.
상·하류 제품 정보
상류 원료
공급사50 곳
관련 반응
연결된 노트
불러오는 중…